Tracing Metabolic Inflexibility in Fanconi Anemia 

• by Henry Thomas

• February 10, 2026

Virtual Staining and the Next Era of Pathology

How AI enables scalable biomarker analysis that preserves tissue samples, addressing some of the most persistent bottlenecks in clinical care and research

• by Kenneth To

• June 19, 2026

• 6 min

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

• July 1, 2026

• 1 min

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

• by

• June 24, 2026

• 4 min